Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Debt / NOTE 3.250%11/0
-
Market price (% of par)
-
86.5%
-
Total 13F principal
-
$223,351,500
-
Principal change
-
-$12,380,500
-
Total reported market value
-
$193,184,303
-
Number of holders
-
25
-
Value change
-
-$12,104,761
-
Number of buys
-
9
-
Number of sells
-
7
Institutional Holders of THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 as of Q2 2019
As of 30 Jun 2019,
THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 was held by
25 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$223,351,500
in principal (par value) of the bond.
The largest 10 bondholders included
CITADEL ADVISORS LLC, BAUPOST GROUP LLC/MA, WOLVERINE ASSET MANAGEMENT LLC, Kohlberg Kravis Roberts & Co. L.P., ZAZOVE ASSOCIATES LLC, Linden Advisors LP, Verition Fund Management LLC, DeepCurrents Investment Group LLC, Context Capital Management, LLC, and FMR LLC.
This page lists
25
institutional bondholders reporting positions
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.